Related Experiment Video
Updated: Jul 7, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Histone Deacetylase Class IIb Inhibition Improves Amyloid-β-induced Learning and Memory Deficits in Male Rats.
Zahra Mansouri1,2, Fereshteh Motamedi2, Fariba Khodagholi2
1Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Basic and Clinical Neuroscience
|July 6, 2026
Summary
Inhibiting histone deacetylases (HDACs) like HDAC6 and HDAC10 shows promise for treating Alzheimer's disease (AD). This study found that HDAC inhibition improved memory and learning deficits in a rodent model of AD.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline.
- Key pathological hallmarks of AD include amyloid-beta (Aβ) aggregation and tau hyperphosphorylation.
- Histone deacetylases (HDACs) are implicated in the pathophysiology of neurodegenerative diseases.
Purpose of the Study:
- To investigate the neuroprotective potential of inhibiting HDAC6 and HDAC10 in a rodent model of Alzheimer's disease.
- To evaluate the effects of specific HDAC inhibitors on cognitive function and molecular changes in the hippocampus.
Main Methods:
- Alzheimer's disease-like cognitive deficits were induced in Wistar rats via bilateral intra-hippocampal Aβ injections.
- Rats received microinjections of Tubacin (HDAC6 inhibitor) or bufexamac (HDAC6 and 10 inhibitors) post-Aβ administration.
- Hippocampal molecular changes were assessed using western blotting for pCREB/CREB and Pp70/P70 ratios.
Main Results:
- Bufexamac significantly ameliorated learning and memory impairments in the Morris water maze (MWM) task.
- Tubacin administration improved memory deficits but did not impact learning.
- Both HDAC inhibitors increased pCREB/CREB and Pp70/P70 ratios in the hippocampus, correlating with behavioral improvements.
Conclusions:
- HDAC IIb inhibition represents a potential therapeutic strategy for cognitive impairments in Alzheimer's disease models.
- Targeting HDACs offers a promising avenue for further research and development of AD treatments.
